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Pilomatricoma consists of the cells differentiating towards hair matrix cells. Immunohistochemical study revealed
the deposition of type II collagen in the overlying dermo-epidermal junction (DEJ) of this benign tumor. Proa1(II)
mRNA was detected by RT-PCR in the overlying epidermal layer but not in the dermal layer prepared from the
lesional skin of pilomatricoma. The neutral salt-soluble proteins extracted from the tumor of pilomatricoma induced
proa1(II) mRNA in the cultured human keratinocytes but not in the cultured dermal ﬁbroblasts. Bone morphogenetic
protein 2 or 4 (BMP2 or 4) was immunohistochemically detected in some shadow cells of pilomatricoma.
Recombinant BMP2 and BMP4 were found to induce proa1(II) mRNA concentration dependently in the cultured
human keratinocytes but not in the cultured ﬁbroblasts. Proa1(II) mRNA induced by BMP2 and in cultured
keratinocytes contained exon 2, indicating that the mRNA species is non-chondrogenic type IIA form. The results
strongly suggest that BMP2 or 4 expressed in pilomatricoma is responsible for the induction of proa1(II) collagen
mRNA in the overlying epidermal cells resulting in the deposition of type II collagen in the DEJ. When human
keratinocytes were cultured on type II collagen substratum in vitro, the cell proliferation was accelerated at the
early period of culture but was inhibited at the late period of culture, whereas the cell proliferation was persistently
accelerated by type I or IV collagen substratum. Type II collagen deposition in the DEJ may potentially exert
profound effects on keratinocyte proliferation and differentiation.
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Pilomatricoma or calcifying epithelioma of Malherbe is a
benign cutaneous epithelial tumor, and morphologically
composed of small basophilic cells and large, probably
non-viable shadow cells as well as transitional cells
between basophilic and shadow cells (Forbis and Helwig,
1961). Previous immunohistochemical and histochemical
studies demonstrated that majority of pilomatricoma cells
are considered to be differentiating cells towards hair-
forming cells, particularly hair cortex cells, of hair follicles
(Moll et al, 1988; Watanabe et al, 1994). The mechanism of
epidermal cell differentiation towards hair matrix cells
remains to be determined. Recently b-catenin, a participant
in the Wnt signaling, has been shown to play an important
role in the morphogenesis of hair follicles and the
tumorigenesis of fair follicle-related tumors including pilo-
matricomas. b-catenin is essential for fate decisions of stem
cells between the formation of follicular and epidermal
keratinocyte lineages (Gat et al, 1998; Huelsken et al, 2001),
and 26% or 75% of pilomatricomas possess activating
mutations in exon 3 of b-catenin gene (Chan et al, 1999;
Moreno-Bueno et al, 2001).
Bone morphogenetic proteins (BMPs) are considered to
be members of transforming growth factor b superfamily
based on their amino acid sequence homology. BMPs
exhibit chondrogenic and osteogenic properties in vivo and
in vitro (Wozney et al, 1988). For examples, implantation of
recombinant human BMP in rat induces bone formation
(Wang et al, 1990). Incubation of bone marrow-derived
mesenchymal progenitor cells with BMP induces chondro-
genic differentiation in vitro (Johnstone et al, 1998; Sekiya
et al, 2001). Besides the chondrogenic or osteogenic
activity, BMP2 and BMP4 are potential hair follicle initiation
factors and regulators of hair cycle (Blessing et al, 1993;
Botchkarev, 2003). Increased evidences suggest that the
expression of BMP depends on b-catenin during follicular
formations and hair cycling, although whether BMP is a
direct or indirect target gene of b-catenin signaling in hair
formation is currently unknown (Huelsken et al, 2001).
Type II collagen is the major and unique collagenous
component of cartilage and plays a critical role in
chondrogenesis during embryonic development (Mayne
and von der Mark, 1983). It has been demonstrated that
Abbreviations: DEJ, dermo-epidermal junction; EDTA, ethylene-
diaminetetraacetic acid; Ig, immunoglobulin; NEM, N-ethyl-
maleimide; PMSF, phenylmethylsulfonylfluoride; SDS, sodium
dodecylsulfate; SSC, 0.15 M sodium chloride and 0.015 M sodium
citrate
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type II collagen is much more widely distributed during early
development than previously thought. Type II collagen is
detected in non-chondrogenic tissues including embryonic
notochord (Linsenmayer et al, 1973; Miller, 1974), corneal
epithelium (Linsenmayer et al, 1977), neural retina (Smith
et al, 1976), ectodermal-mesenchymal interfaces through-
out the trunk of the chick embryo at the very early stages
(stages 14–19; days 2–3) (Thorogood et al, 1986; Kosher
and Solursh, 1989) and the subepidermal matrix of mouse
hindlimb (stage 31; 7.5 d) which subsequently disappears
with development (Fitch et al, 1989, 1990). We have
previously demonstrated that type II collagen is detected
in the dermo-epidermal junction (DEJ) excluding the region
at which the hair follicles are forming in the human fetal
scalp skin at the stages of 17–23 fetal weeks (Azuma et al,
1994), implying that type II collagen expression in the DEJ
precedes the formation of hair follicles in the fetal skin
development.
In the course of the studies exploring the expression of
type II collagen in the postnatal skin, we found the
expression of type II collagen in the overlying DEJ of
pilomatricoma and demonstrated that the induction was
mediated by BMP2 or BMP4 detected in the tumor cells.
We further studied the influence of type II collagen
deposition on keratinocyte growth and differentiation in
the cell culture system. The results in this study indicate
that keratinocytes in the postnatal skin is still pluripotential
and can express type II collagen under the pathological
condition.
Results
Detection of type II collagen in overlying DEJ of
pilomatricoma and localization of proa1(II) mRNA Im-
munohistochemical study of pilomatricoma using anti-type
II collagen antibody demonstrated that four cases of
pilomatricoma exhibited a strong staining in the overlying
DEJ. The immunoreactivity was restricted in DEJ, and no
apparent immunoreactivity was found in the dermal
matrices (Fig 1a and b). Normal skins obtained from benign
skin tumors including epidermal cyst (n¼5) and nevus cell
nevus (n¼5) showed negative reaction with this antibody
(Fig 1c).
Localization of proa1(II) mRNA was studied by RT-PCR
using the RNA prepared from the lesional epidermis and
dermis of cases 1 and 2 pilomatricomas. Specific 369 bp
fragment of proa1(II) mRNA was found to be detected
preferentially in the overlying epidermis of pilomatricoma
not in the dermis in both cases (data not shown).
Detection of BMP2 or BMP4 in pilomatricoma Paraffin-
embedded sections were incubated with anti-BMP2/4
antibody. BMP2/4 was detected in some shadow cells
of pilomatricoma in both cases 1 and 2 but not in the
basophilic or transitional cells (Fig 2), which was consistent
with the previous report (Kurokawa et al, 2000). There was
no immunoreactivity of BMP2/4 in the overlying epidermal
cells and dermal cells (not shown).
BMP2 and BMP4 induce type II collagen expression in
cultured human keratinocytes We first speculated that
some soluble factor(s) may be secreted from the tumor
and act on basal keratinocytes to induce the expression of
type II collagen. In order to prove this, tumor mass of
pilomatricoma was homogenized and sonicated in the
neutral buffer (0.1 M Tris-HCl, pH 7.5, containing protease
inhibitor cocktail). Human keratinocytes and fibroblasts
were treated with the homogenate of pilomatricoma at the
dose of 10 mg per mL medium for 24 h. RT-PCR clearly
showed that the homogenate induced 369 bp fragment of
proa1(II) mRNA in the cultured keratinocytes but not in the
cultured fibroblasts (Fig 3a). To identify the factor(s) in
the homogenate, ELISA was done using the antibodies for
various factors including tumor necrosis factor-a (TNF-a),
tumor growth factor-b (TGF-b), and interleukin-1b (IL-1b).
But these factors gave negative results (not shown).
Because the result of immunohistochemistry of shadow
cells of piloatricoma with the antibody for BMP2/4 strongly
suggested that the candidate factors were BMP2 and
Figure1
Immunohistochemical staining of the overlying skin of pilomatri-
coma with monospecific anti-type II collagen antibody. Overlying
skins of case 1 (a) and case 2 (b) of pilomatricoma and normal skin (c)
were incubated with anti-type II collagen antibody at 1:40 dilution, then
with biotin-conjugated anti-mouse immunoglobulin antibody. Localiza-
tion of antigen was visualized with avidin–biotin complex (original
magnification  100).
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BMP4, we continued the further study focusing on BMP2
and BMP4.
To prove the type II collagen-inducible activity of BMP2
and BMP4 directly, we studied whether proa1(II) mRNA is
induced in the cultured human keratinocytes by the
treatment of various amount of BMP2 or BMP4. RT-PCR
demonstrated that specific 369 bp fragment of proa1(II)
transcript was detected after the treatment of BMP2 and
BMP4 at the concentrations higher than 100 ng per mL (Fig
3b). By contrast, dermal fibroblasts did not induce proa1(II)
transcript by BMP2 and BMP4 (not shown) at the conc-
entrations tested here. Pre-treatment of the cells with
recombinant human noggin (1.6 ng per mL) inhibited
BMP2-inducible proa1(II) transcript enhancement (Fig 3c).
Structual analysis of proa1(II) mRNA induced in over-
lying epidermis and cultured keratinocyte Since it has
been demonstrated that type II procollagen is expressed in
two structurally different mRNAs by alternative splicing of
the primary gene transcript that either include (type IIA) or
exclude (type IIB) an exon 2 encoding the major portion
of the amino terminal propeptide (Ryan and Sandell, 1990;
Sandell et al, 1991), we performed the structural analysis of
proa1(II) mRNA induced by BMP2 and BMP4 in the cultured
keratinocytes. One single fragment of 377 bp in both BMP2-
and BMP4-treated keratinocytes was detected by RT-PCR
(Fig 4a, lanes 2 and 4), whereas 171 bp fragment was
detected in the auricular cartilage (Fig 4a, lane 5), indicating
that proa1(II) mRNA species induced by BMP2 and BMP4 is
type IIA form and those of auricular cartilage is type IIB
form. To confirm this result, RT-PCR products were blotted
onto the filters and hybridized with the oligonucleotide
probe spanning 30 end of exon 1 and 50 end of exon 2. A 377
bp fragment was detected by autoradiography in both
BMP2- and BMP4-treated keratinocytes but 171 bp
fragment in the ear cartilage was not (Fig 4b), indicating
that proa1(II) mRNA species was type IIA form.
Type II collagen substratum inhibits keratinocyte pro-
liferation in late phase of culture In order to investigate
the biological significance of type II collagen accumulated in
the DEJ, effect of type II collagen on keratinocyte prolifera-
tion was studied in vitro. Cells were plated at a relatively low
density of 1  103 per 32 mm diameter dishes to observe
the change of cell growth for longer periods. Type II collagen
substratum as well as types I and IV collagen substrata
showed a growth-promoting effect at the early phase in
culture (days 4 and 6 in culture) but type II collagen
substratum exhibited a significant inhibiting effect at the late
phase of culture (days 12 and 14 in culture) (po0.01) when
type I collagen and type IV collagen still showed growth-
stimulating effect (Fig 5). A considerable number of cells on
Figure 2
Immunohistochemical detection of bone morphogenetic protein 2
or 4 (BMP2 or BMP4) in pilomatricoma. Skin specimens obtained
from cases 1 and 2 were incubated with anti-BMP2/4 antibody for 24 h
at 41C, then incubated with biotin-conjugated anti-goat Ig antibody at
1:500 dilution for 2 h at room temperature. Antigen–antibody complex
was reacted with avidin–biotin complex. Original magnification is
 100. S, shadow cell.
Figure 3
Proa1(II) collagen transcript is induced in cultured human keratinocytes by the homogenate prepared from pilomatricoma, or by
recombinant human bone morphogenetic protein 2 and 4 (BMP2 and BMP4). Cultured keratinocytes and fibroblasts were treated with the
homogenate prepared from pilomatricoma (a), or cultured keratinocytes were treated with recombinant BMP2 and BMP4 (b), or treated with the
combination of recombinant BMP2 and recombinant noggin (c). RNA was isolated from the cultured keratinocytes. RT-PCR was performed using
proa1(II) (upper panel) and b-actin (lower panel) primer pairs. PCR products were analyzed by an electrophoresis on agarose gel. (a) Keratinocytes
were treated for 24 h without (lane 1) or with (lane 2) the homogenate isolated from pilomatricoma. Fibroblasts were treated for 24 h with the
homogenate (lane 3). (b) Keratinocytes were treated for 24 h with 0 (lane 1), 25 (lane 2), 100 (lane 3), and 250 ng per mL (lane 4) BMP2, or treated with
0 (lane 5), 25(lane 6), 100 (lane 7), and 250 (lane 8) ng per mL BMP4. (c) Keratinocytes were treated for 24 h with 100 ng per mL BMP2 alone (lane 1)
or with the combination of 100 ng per mL BMP2 and 1.6 ng per mL noggin (lane2). M indicates molecular markers of 770, 612, 495, 392, 341, 297,
210 bp. M0 indicates molecular markers of 1360, 1107, 926, 658, 489, 267 bp.
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type II collagen substratum on days 12 and 14 was found to
float in the medium under a microscope (not shown).
Discussion
We have found type II collagen deposition in overlying DEJ
of pilomatricoma. Overlying epidermal keratinocytes will be
responsible for the expression of type II collagen because
type II collagen mRNA was detected in the overlying
epidermis not in the dermal tissue, and type II collagen
mRNA was induced by BMP2 and BMP4 treatments in the
cultured keratinocytes but not in the cultured fibroblasts.
This is an interesting observation because extracellular
matrix proteins in DEJ including type IV collagen are
considered to be produced through epidermal–dermal
interaction (Fleischmajer et al, 1993; Marinkovich et al,
1993). In addition, transient expression of type II collagen in
the ectodermal–mesenchymal interfaces during the early
stage of chick embryonic development is considered to be
mediated by epithelial–mesenchymal interaction (Thoro-
good et al, 1986; Kosher and Solursh, 1989).
We have found that the homogenate extracted from
pilomatricoma by neutral salt is capable of inducing type II
collagen expression in cultured keratinocytes. In the course
of searching the candidate growth factor or cytokines
responsible for the type II collagen induction, we found
BMP2/4 expression in the shadow cells of pilomatricoma
but not in the other cell components of pilomatricoma. On
the basis of the hypothesis that BMP2 and BMP4 are potent
inducible factor of type II collagen, we treated the cultured
keratinocytes with BMP2 and BMP4 and found their type II
collagen-inducing activity. This was confirmed by the
experiment that the induction of type II collagen by BMP2
was abolished in the presence of noggin, a specific agonist
of BMP2 and BMP4. We have tested some other cytokines
and growth factor such as TGF-b1, TNF-a, or IL-1b but
failed to find such activities (not shown). This suggests that
BMP2 and BMP4 produced and secreted by shadow cells
of pilomatricoma act on overlying epidermis to induce type
II collagen. In fact, in the normal-appearing skin external
from pilomatricoma type II collagen deposition in DEJ was
not be able to be detected (not shown). These results are
consistent with the previous studies that the expression of
BMPs have an essential role in cutaneous tumorigenesis
(Blessing et al, 1995, 1996; Wach et al, 2001).
The question whether type II expression in DEJ is the
cause or result of pilomatricoma is still unclear. We initially
thought that some factors involving in the differentiation of
stem cells towards hair cortex cells in the tumorigenesis of
pilomatricoma are also involved in the induction of type II
collagen expression in the DEJ. But the presence of
detectable BMP2/4 in the shadow cells of pilomatricoma
and type II collagen-inducing potential of BMP2 and BMP4
in cultured keratinocytes may suggest that pilomatricoma
itself potentially expresses BMP2/4 which induces the
expression of type II collagen in the DEJ. Therefore we at
present think that type II collagen expression is the result
rather than cause of pilomatricoma.
Figure 4
Alternative splicing of exon 2 of type II collagen
primary transcript expressed by cultured keratino-
cytes in the presence of bone morphogenetic
protein 2 or 4 (BMP2 or BMP4). (a) Keratinocytes
were treated without (lanes 1 and 3) or with either
BMP2 (250 ng per mL) (lane 2) or BMP4 (250 ng per
mL) (lane 4) for 48 h. RNA was isolated and RT-PCR
was performed using upstream (exon 1) and down-
stream (exon 5) primers of proa1(II) (upper panel) and
b-actin (lower panel). PCR product was analyzed by
agarose gel electrophosesis. Positive control assays
were done using the RNA isolated from ear cartilage
(lane 5). M indicates molecular markers of 770, 612,
495, 392, 341, 297, 210 bp. (b) RT-PCR products were
blotted onto filters and hybridized with the radiola-
beled oligonucleotide probe spanning 30 end of exon 1
and 50 end of exon 2. The filters were washed and
subjected to autoradiography.
Figure 5
Cell proliferation of cultured keratinocytes is suppressed in type II
collagen-coated dishes. Human keratinocytes were plated at an intial
density of 1  103 per dish on type I(open circle), type II (open triangle),
type IV collagen-coated (closed triangle) or plain (closed circle) dishes
and maintained in KGM over 14 d. Cell number was counted every 2 d
after trypsin treatment. Values are mean  SEM from two sets of
assays done in triplicate. Statistical significance at po0.01 is indicated
by  and .
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Type II collagen has been reported to be expressed in
two mRNAs by differential splicing of the primary gene
transcript that either includes (type IIA) or excludes (type IIB)
an exon 2 encoding the major portion (69 amino acids) of
the amino terminal propeptide (Ryan and Sandell, 1990).
Each procollagen mRNA has a distinct tissue distribution
during chondrogenesis, with type IIB expressed in chon-
drocyte and type IIA expressed in the chondroprogenitor
cells surrounding the cartilage (Sandell et al, 1991). Proa1(II)
mRNA induced by BMP2 and BMP4 was found to contain
exon 2 (type IIA), indicating that type II collagen in DEJ of
pilomatricoma is non-chondrogenic from (type IIA).
Physiological significance of type II collagen in the DEJ
is uncertain at present. Accumulated type II collagen in
the DEJ may exert a profound influence on the stability of
DEJ as well as the differentiation of keratinocytes and
the structural organization of adjacent extracellular matrix
components (such as anchoring fibrils) in the subepidermal
region since in the normal condition type II collagen never
exists in this area except a very short duration of chick
embryonic and human fetal skin development (Azuma et al,
1994). Transient expression of type II collagen in chick
embryonic and human fetal scalp skins is thought to be
related to the development of feather and hair follicle,
because this collagen starts to diminish at the restricted
sites where feather buds and hair follicles are being
developed. If type II collagen induction in the overlying
DEJ of pilomatricoma occurs by the same mechanism
as seen in the chick embryonic and human fetal skin
development, type II collagen in pilomatricoma induced by
BMP2/4, which are potent hair follicle initiation factors
(Blessing et al, 1993), will be a preceding marker protein of
the induction of hair follicles. Keratinocyte differentiation to
hair matrix occurs in the lesions other than pilomatricomas
such as follicular cysts and cutaneous mixed tumors (LeBoit
et al, 1987). We found type II collagen accumulation in
the overlying DEJ of some cases of trichilemmoma and
cutaneous mixed tumor as well (manuscript in preparation).
This will also support the idea that type II collagen
expression in the DEJ is related to follicular differentiation
of keratinocytes.
Previous experiments have shown that extracellular
matrices like types I and IV collagens, fibronectin, and
laminin influence keratinocyte adhesion, spreading, prolif-
eration, and differentiation (Kubo et al, 1987; Adams and
Watt, 1989; Guo and Grinnell, 1989; Woodley et al, 1990). In
fact, type I or IV-, fibronectin-, and laminin-coated plastic
dishes have been used to efficiently maintain keratinocyte
growth in culture. The interaction between keratinocytes
and type II collagen has never been studied because
expression of type II collagen has never been expected in
DEJ or subepidermal area of the skin. It is noted that type II
collagen, like other extracellular matrices, promoted kera-
tinocyte proliferation at the early stage of culture, but unlike
other extracellular matrices, inhibited keratinocyte prolifera-
tion. It is uncertain that the biphasic effect of type II collagen
substratum on keratinocyte proliferation is due to the
difference of cell density during the cell proliferation or
due to the switching of cell signaling pathway mediated by
the interaction between keratinocyte and type II collagen.
The histological changes in the overlying epidermis of
pilomatricoma such as the formation of horn cyst, prolifera-
tion of basalioma-like cells (Aso et al, 1990), or abnormal
elongation of epidermal rete ridge (histologically seen in
case 1 in Fig 1) may be related to the altered keratinocyte
differentiation induced by the accumulation of type II
collagen in the DEJ.
Materials and Methods
Skin samples Skin samples were obtained from four cases of
pilomatricoma under the permission of the patients and subjected
to histological and biological analysis. Case 1: 22-y-old Japanese
woman noticed skin nodule on the right arm for 1 y. Physical
examination showed 21  25 mm intradermal tumor with clear
border. Case 2: 15-y-old Japanese girl presented with asympto-
matic dermal tumor with the diameter of 12 mm on the neck. She
noticed the tumor 3 y before. Case 3: 17-y-old Japanese boy
presented with asymptomatic dermal tumor with the diameter of
15 mm on the back. He noticed the tumor 3 y before. Case 4: 16-y-
old Japanese girl presented with asymptomatic dermal tumor with
the diameter of 30  25 mm on the back. She noticed the tumor
2 y before. The skin tumors were resected by a surgical operation.
Histological diagnosis of pilomatricoma was done with hematox-
ylin–eosin stain. Normal skins (n¼ 10) were obtained from normal-
appearing area of benign skin tumors (epidermal cyst and nevus
cell nevus).
Immunohistochemistry Skin samples were fixed in 10% buffered
formalin, embedded in paraffin and cut into 5 mm sections. The
sections were pre-treated with pronase (0.1% in phosphate-
buffered saline) (type XX TV, Sigma, St Louis, Missouri) for 30
min, then incubated for 24 h at 41C with monoclonal anti-human
type II collagen antibody (Fuji Chemical Industries, Toyama,
Japan) at 1:40 dilution, anti-human polyclonal BMP2/4 antibody
(Genzyme/Techne, Minneapolis, Minnesota) at 1:100 dilution. The
sections were incubated with biotin-conjugated anti-mouse
immunoglobulin (Ig) antibody or anti-goat Ig antibody (Dako,
Glostrup, Denmark) at 1:500 dilution for 2 h at room temperature.
Antigen–antibody complex was reacted with peroxidase-labeled
avidin–biotin complex (Dako) for 30 min. The reaction was
visualized with 3-amino-9-ethylcarbazole. The sections were
counterstained with hematoxylin. The specificity of anti-type II
collagen antibody has been previously demonstrated by western
blot assay (Azuma et al, 1994) and immunohistochemical studies
using the specimen of human auricular cartilage (not shown).
Cell culture and treatment Normal human keratinocytes (NHKs)
were purchased from Sanko-Junyaku (Tokyo, Japan) and cultured
in serum-free, low-calcium (0.09 mM), modified MCDB 153
keratinocyte basal media containing the following growth factors,
insulin, epidermal growth factor (EGF), hydrocortisone and bovine
pituitary extract (BPE) (designated as KGM). NHKs at third or fourth
culture were used in this study according to supplier’s recommen-
dation. Normal human skin fibroblast culture was established by
explant method. Fibroblasts were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). Cells were plated at a density of 1  104 in 35 mm
diameter dishes and grown for 6 d. Tumor mass (  1 g wet weight)
was homogenized in 2 mL of 50 mM Tris-HCl, pH 7.4, containing
protease inhibitor cocktail (1 mM EDTA, NEM, and PMSF) with
a dounce homogenizer, and sonicated with five 30 s bursts
(Handy Sonic UR-20P, Tomy Seiko Co., Tokyo, Japan) at 41C.
The homogenate was cleared by centrifugation at 15,000 g for
30 min at 41C. The protein content of the supernatant was measure
by absorbance at 280 A˚. Cells were treated with the homogenate
(final concentration; 10 mg per mL medium) for 24 h or human
recombinant BMP2 and BMP4 (Pharma Biotechnology, Hannover,
Germany) for 24 h at the doses of 0–250 ng per mL. To study the
BMP-specific induction of type II collagen expression, cells were
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treated for 24 h with the combination of BMP2 (100 ng per mL) and
recombinant human noggin (1.6 ng per mL) (Pepro Tech EC Ltd,
London, UK), a potent agonist for BMP2 and BMP4 (Zimmerman,
1996).
To study the effect of type II collagen on keratinocyte
proliferation, cells were plated at a density of 1  103 per 35 mm
diameter matrix-coated dishes containing either type I collagen
from rat tail tendon, type II collagen from bovine cartilage or type IV
collagen from human placenta (Beckton-Dickinson Labware,
Bedford, MA). The matrix-coated dishes were prepared by the
incubation of tissue culture dishes with these matrix proteins at the
concentration of 10 mg per mL for 24 h at 41C, followed by rinse
with KGM twice before use (Kubo et al, 1987). Cells were grown in
KGM for 14 d. On days 4, 6, 8, 10, 12, and 14 in culture, the cells
were trypsinized and cell number was counted with a Coulter
counter. Assays were performed twice in triplicate. Values were
expressed by mean  SEM. Statistical significance was calculated
by one-sided Student’s t test and p-value below 0.05 was
considered to be significant.
RNA extraction and RT-PCR Total cellular RNA was isolated from
the cultured keratinocytes or dermal fibroblasts with guanidine
thiocyanate (Chomczynski and Sacchi, 1987), and adjusted to a
concentration of 1 mg per mL. In an experiment, to separate the
epidermis from dermis, the lesional skins of the pilomatricomas
were cut into small pieces (  1 cm3) and treated with 0.5%
dispase (Sanko-Junyaku) at 41C for 2 h. Epidermal layer was
peeled off from the dermal layer by sterile forceps, then RNA was
immediately isolated from both layers. For a control experiment,
RNA was prepared from auricular cartilage obtained from surgical
operation of squamous cell carcinoma on the ear. The exon-
specific primer pairs; 50ACACTCAAGTCCCTCAACAACCAGAT30
for upstream primer and 50GACGTCCAGATGACCTTCCTGC-
GCCTG30 for downstream primer at the C-terminal propep-
tide domain of human proa1(II) chain (Sangiorgi et al, 1985)
were synthesized. For internal standard, the upstream primer
50TTAATGTCACGCACGATTTCCC30 and the downstream primer
50GTGATGGTGGCATGGGTCA30 of b-actin cDNA (Ponte et al,
1984) were also synthesized. Total RNA (1 mg) was used for first
strand cDNA synthesis. RT-PCR was performed in the presence of
3 pmol of a 30-oligonucleotide and 35 U of reverse transcriptase
from avian myoblastosis virus (Takara Shuzo Co., Otsu, Shiga,
Japan) in a total reaction volume of 20 mL (Kawasaki, 1990). The
resulting cRNA was then subjected to the first PCR using 25 pmol
50-oligonucleotide and additional 30-oligonucleotide in a total
volume of 100 mL. The cDNA was amplified for 35 cycles at 941C
per 1 min, 581C per 1 min, and 721C per 2 min. Analysis of all the
PCR products was performed by agarose (1.5%) gel electrophor-
esis followed by ethidium bromide staining. The PCR products
were subcloned into a TA cloning vector (Invitrogen Corp., San
Diago, California). Plasmid DNA was isolated (Wizard plus
Miniprep, Promega Corp., Madison, Wisconsin), and subjected to
nucleotide sequencing by dideoxy chain termination method
(Sanger et al, 1977) to identify the cloned cDNA.
Structural analysis of proa1(II) mRNA To analyze the splicing of
exon 2 of proa1(II) mRNA, the upstream primer 50ATGATTCG30
corresponding to the exon 1 sequences of proa1(II) cDNA and
downstream primer 50AGGCCCAGGAGGTCCTTTGGG30 corre-
sponding to exon 5 sequences were synthesized (Sangiorgi et al,
1985). RNA was isolated from cultured keratinocytes which had
been treated with BMP2 and BMP4. RT-PCR was performed as
described above. Result of RT-PCR is expected to give PCR
product with 377 bp in type IIA mRNA and 171 bp in type IIB
mRNA.
To confirm the expression of proa1(II) mRNA species in which
exons 1 and 2 are contiguous, a 24 bp oligonucleotide probe
(50TGCCAGCCTCCTGGACATCCTGGC30) corresponding to 12
nucleotides at 30 end of exon 1 and 12 nucleotides at the 50 end
of exon 2 was synthesized as previously described (Ryan and
Sandell, 1990), then radioactively labeled at 50 end with [g-32P]ATP
(210 TBq per mmol, Amersham, Biosciences Corp., Piscataway,
New Jersey) and T4 polynucleotide kinase. RT-PCR products
which had been resolved on 1.5% agarose gel were capillary-
transferred onto nylon filters, then hybridized at 271C overnight
with the exons 1–2-specific oligonucleotide probe in a solution of
50 mM Tris-HCl, pH 7.5, 1 M NaCl, 10% dextran sulfate, 1% SDS,
and 100 mg per mL tRNA. The filters were washed twice with
1  SSC at 551C for 2 h, then subjected to autoradiography.
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